2024 Society of Urologic Oncology (SUO) Annual Meeting
SUO 2024 Prostate Cancer
- SUO 2024: Joseph A Smith, Jr. Mentorship Award Lecture
- SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radical Prostatectomy
- SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radiotherapy
- SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Focal Ablation
- SUO 2024: Sustainability in Prostate Cancer Care
SUO 2024 Bladder Cancer
- SUO 2024: Sexual Dysfunction and Radical Cystectomy
- SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting
- SUO 2024: ABLE-32: A Randomized, Controlled, Phase IIIB Clinical Trial of Nadofarogene Firadenovec-vcng versus Observation in Patients with Intermediate-risk, Non-muscle Invasive Bladder Cancer
- SUO 2024: Preventing and Managing Long Term Complications of Radical Cystectomy
- SUO 2024: Exploratory Analysis of Post-treatment Outcomes in Patients with Bacillus Calmette-Guerin-unresponsive High-risk, Non-muscle Invasive Bladder Cancer Who Experienced Non-Response to Pembrolizumab Monotherapy in KEYNOTE-057
SUO 2024 Kidney Cancer
- SUO 2024: Biomarkers and Clinical Predictors in RCC
- SUO 2024: Update on Neoadjuvant Therapy Trials in RCC
- SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting
- SUO 2024: Phase 1B/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC
- SUO 2024: Advances in RCC Molecular Imaging and Theranostics
SUO 2024 Penile, Urethral, Testicular, and Adrenal Cancers
- SUO 2024: Adjuvant Chemotherapy after Primary RPLND for Seminoma - When, Who, if Ever?
- SUO 2024: Top Papers in Testicular Cancer 2024
- SUO 2024: Spotting Metastatic Masqueraders: How to Avoid Inappropriate Chemotherapy Administration for Testicular Cancer
- SUO 2024: Updates to Testicular Cancer Epidemiology
- SUO 2024: Strategies for RPLND in Metastatic Testicular Seminoma
SUO 2024 Upper Tract Urothelial Cancer
- SUO 2024: Efficacy and Safety of Padeliporfin VTP for Treatment of Low-Grade UTUC: ENLIGHTED Phase 3 study
- SUO 2024: Voided Urine Cell-Free DNA as a Biomarker for Upper Tract Urothelial Carcinoma
- SUO 2024: Long-Term Outcomes of Primary Chemoablation of Low-Grade UTUC with UGN-101, a Mitomycin Reverse Thermal Gel